Preclinical Studies of Pf-04849285,An Interferon-α8 Fusion Protein for the Treatment of HCV

Nelson D.R. , Rustgi V. , Balan V. Safety and antiviral activity of albinterferon alfa-2b in prior interferon non responders with chronic hepatitis C. Clin Gastroenterol Hepatol 2009; 7: 212–218.

Zeuzem S. , Yoshida E.M. , Benhamou Y. Albinterferon alfa-2b dosed every two or four weeks in interferon-naive patients with genotype 1 chronic hepatitis C. Hepatology 2008; 48: 407–417.

Nelson D.R. , Benhamou Y. , Chuang W.L. Albinterferon alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3. Gastroenterology 2010; 139: 1267–1276.

Zeuzem S. , Sulkowski M. , Lawitz E. Efficacy and safety of albinterferon alpha-2B in combination with ribavirin in treatment-naive, chronic hepatitis C genotype 1 (CHC G1) patients. J Hepatol 2009; 50 Suppl 1: S377.

Hilkens C.M.U. , Schlaak J.F. , Kerr I.M. Differential responses to IFN-alpha subtypes in human T cells and dendritic cells. J Immunol 2003; 171: 5255–5263.

Evinger M. , Rubinstein M. , Pestka S. Antiproliferative and antiviral activities of human leukocyte interferons. Arch Biochem Biophys 1981; 210: 319–329.

Fish E.N. , Banerjee K. , Stebbing N. Human leukocyte interferon subtypes have different antiproliferative and antiviral activities on human cells. Biochem Biophys Res Commun 1983; 112: 537–546.

van Pesch V. , Lanaya H. , Renauld J-C . Characterization of the murine alpha interferon gene family. J Virol 2004; 78: 8219–8228.

Szubin R. , Chang W.L. , Greasby T. Rigid interferon-alpha subtype responses of human plasmacytoid dendritic cells. J Interferon Cytokine Res 2008; 28: 749–763.

Aguet M. , Grobke M. , Dreiding P. Various human interferon alpha subclasses cross-react with common receptors: the binding affinities correlate with their specific biological activities. Virology 1984; 132: 211–216.

Meister A. , Uze G. , Mogensen K.E. Biological activities and receptor binding of two human recombinant interferons and their hybrids. J Gen Virol 1986; 67: 1633–1643.

Piehler J. , Schreiber G. Biophysical analysis of the human type I interferon receptor ifnar2 expressed in E. coli with interferon alpha2. J Mol Biol 1999; 289: 57–67.

Heathcote J. Consensus interferon: a novel interferon for the treatment of hepatitis C. J Viral Hepat 1998; 5: 13–18.

Foster G.R. , Rodrigues O. , Ghouze F. Different relative activities of human cell-derived interferon-alpha subtypes: IFN-alpha 8 has very high antiviral potency. J Interferon Cytokine Res 1996; 16: 1027–1033.

Koyama T. , Sakamoto N. , Tanabe Y. Divergent activities of interferon-alpha subtypes against intracellular hepatitis C virus replication. Hepatol Res 2006; 34: 41–49.

Yamaoka T. , Kojima S. , Ichi S. Biologic and binding activities of IFN-alpha subtypes in ACHN human renal cell carcinoma cells and Daudi Burkitt's lymphoma cells. J Interferon Cytokine Res 1999; 19: 1343–1349.

Brideau-Andersen A.D. , Huang X. , Chang Sun S-C . Directed evolution of gene-shuffled IFN-alpha molecules with activity profililes tailored for treatment of chronic viral diseases. Proc Natl Acad Sci U S A 2007; 104: 8269–8274.

Yamamoto K. , Taniai M. , Torigoe K. Creation of interferon-α8 mutants with amino acid substitutions against interferon-α receptor-2 binding sites using phage display system and evaluation of their biologic properties. J Interferon Cytokine Res 2009; 29: 161–170.

Ciaramella G. , Flores M.V. , Horscroft N.J. , Katragadda M. , Wu J. inventors; Pfizer Limited, assignee. Fusion protein, WO 064758. 2011 June 3.

Armour K.L. , Clark M.R. , Hadley A.G. Recombinant human IgG molecules lacking Fc-gamma receptor I binding and monocyte triggering activities. Eur J Immunol 1999; 29: 2613–2624.

Lata S. , Piehler J. Stable and functional immobilization of histidine-tagged proteins via multivalent chelator head-groups on a molecular poly(ethylene glycol) brush. Anal Chem 2005; 77: 1096–1105.

Lata S. , Gavutis M. , Piehler J. Monitoring the dynamics of ligand-receptor complexes on model membranes. J Am Chem Soc 2006; 128: 6–7.

Lamken P. , Lata S. , Gavutis M. Ligand-induced assembling of the type I interferon receptor on supported lipid bilayers. J Mol Biol 2004; 341: 303–318.

Kalie E. , Jaitin D.A. , Podoplelova Y. The stability of the ternary interferon-receptor complex rather than the affinity to the individual subunits dictates differential biological activities. J Biol Chem 2008; 283: 32925–32936.

Immune epitope database and analysis resource. T cell epitope prediction tools. (Updated 7 August 2009. Accessed 23 September 2008.) Available from http://tools.immuneepitope.org/main/html/tcell_tools.html.

Familletti P.C. , Rubinstein S. , Pestka S. Assay for interferon: a convenient and rapid cytopathic effect inhibition assay for interferon. In Pestka S. (Editor). Methods in Enzymology. Vol. 78. New York: Harcourt 1981; pp. 387–394.

Lohmann V. , Körner F. , Koch J. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110–113.

Pfeffer L.M. , Dinarello C.A. , Herberman R.B. Biological properties of recombinant α-interferons: 40th anniversary of the discovery of interferons. Cancer Res 1998; 58: 2489–2499.

Pestka S. , Krause C.D. , Walter M.R. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004; 202: 8–32.

Jaitin D.A. , Roisman L.C. , Jaks E. Inquiring into the differential action of interferons (IFNs): an IFN-alpha2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-beta. Mol Cell Biol 2006; 26: 1888–1897.

Goodbourn S. , Didcock L. , Randall R.E. Interferons: cell signalling, immune modulation, antiviral responses and virus countermeasures. J Gen Virol 2000; 81: 2341–2364.

Trown P.W. , Wills R.J. , Kamm J.J. The preclinical development of Roferon-A. Cancer 1986; 57: 1648–1656.

Osborn B.L. , Olsen H.S. , Nardelli B. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther 2002; 303: 540–548.

Food and Drug Administration. Toxicologist's review, BLA 99–1488/103949. (Updated 19 December 2000. Accessed 27 September 2008.) Available from http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm094485.pdf.

Subramanian G.M. , Fiscella M. , Lamousé-Smith A. Albinterferon alpha2b: a genetic fusion protein for the treatment of chronic hepatitis C. Nat Biotechnol 2007; 25: 1411–1419.

Huston J.S. , Tai M.S. , McCartney J. Antigen recognition and targeted delivery by the single-chain Fv. Cell Biophys 1993; 22: 189–224.

Stebbings R. , Findlay L. , Edwards C. 'Cytokine storm' in the Phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J Immunol 2007; 179: 3325–3331.

Lange C.M. , Sarrazin C. , Zeuzem S. Review article: specifically targeted anti-viral therapy for hepatitis C – a new era in therapy. Aliment Pharmacol Ther 2010; 32: 14–28.